Multiple Myeloma Coverage from Every Angle

Shaji Kumar, MD, and Prashant Kapoor, MD, on BCL2 Inhibition for the Treatment of Resistant Multiple Myeloma

Posted: Tuesday, July 28, 2020

Shaji Kumar, MD, and Prashant Kapoor, MD, both of the Mayo Clinic, discuss updated results from two abstracts on venetoclax in relapsed or refractory multiple myeloma: the phase III BELLINI trial of venetoclax or placebo in combination with bortezomib and dexamethasone; and a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, with or without bortezomib.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.